Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.
Byakika-Kibwika, Pauline; Lamorde, Mohammed; Okaba-Kayom, Violet; Mayanja-Kizza, Harriet; Katabira, Elly; Hanpithakpong, Warunee; Pakker, Nadine; Dorlo, Thomas P C; Tarning, Joel; Lindegardh, Niklas; de Vries, Peter J; Back, David; Khoo, Saye; Merry, Concepta.
J Antimicrob Chemother
; 67(5): 1217-23, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22316571
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria.
Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.
Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults.
Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
Comparative pharmacokinetics and pharmacodynamics of intravenous artelinate versus artesunate in uncomplicated Plasmodium coatneyi-infected rhesus monkey model.
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria.
Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults.
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.